Cosmo Pharmaceuticals N.V. (“Cosmo”) reports strong preliminary unaudited 2024 revenue and year end cash, reflecting exceptional revenue growth and a solid cash position. Cosmo will publish 2024 audited consolidated financial statements and Annual Report 2024 on March 20, 2025.
– Revenue Growth: Full-year 2024 revenue of €265.7 million (unaudited), marking a 186% increase compared to 2023.
– Financial Strength: Year-end cash and short-term investments of €170.4 million, reflecting a robust balance sheet with zero debt.
– Pipeline Progress: Advancements in one late-stage and three mid- and early-stage programs, with key milestones anticipated in 2025 and 2026.